EMD Millipore Introduces Parteck SRP 80 Excipient

EMD Millipore has introduced Parteck SRP 80, a new functional excipient for oral sustained-release formulations. Parteck SRP 80 is a polyvinyl alcohol (PVA) based excipient for modified-release applications, optimization of pharmacokinetics and pharmacodynamics, as well as bioavailability of actives. The new excipient is fully synthetic, designed to ensure batch-to-batch and performance consistency and facilitating quality by design (QbD) and validation processes.
 
Parteck SRP 80 is suitable for direct compression processes, formulation development, as well as production processes. It is compliant with European Pharmacopoeia (Ph. Eur.), United States Pharmacopoeia (USP) and Japanese Pharmacopoeia Excipients (JPE) and will be part of EMD Millipore’s Emprove program to facilitate regulatory filing and registration processes.
 
“Pharmaceutical excipients play an essential role in the development of safe and effective medicines,” said Andrew Bulpin, eecutive vice president of Process Solutions, EMD Millipore. “Parteck SRP 80 represents a new choice for customers looking to formulate prolonged release oral dosage forms with reliable performance profiles as well as robust and cost efficient production processes, which can translate into improved patient safety and compliance.”